Dwight E Moulin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2347688/publications.pdf

Version: 2024-02-01

71 papers 4,360 citations

30 h-index 65 g-index

73 all docs

73 docs citations

times ranked

73

4405 citing authors

#	Article	IF	CITATIONS
1	Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain, 2003, 105, 71-78.	4.2	433
2	Pharmacological Management of Chronic Neuropathic Pain: Revised Consensus Statement from the Canadian Pain Society. Pain Research and Management, 2014, 19, 328-335.	1.8	397
3	Neuropathic pain: a practical guide for the clinician. Cmaj, 2006, 175, 265-275.	2.0	356
4	Chronic Pain in Canada - Prevalence, Treatment, Impact and the Role of Opioid Analgesia. Pain Research and Management, 2002, 7, 179-184.	1.8	325
5	2012 Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome: Executive Summary. Pain Research and Management, 2013, 18, 119-126.	1.8	299
6	Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain, 2006, 125, 208-215.	4.2	255
7	Sublingual absorption of selected opioid analgesics. Clinical Pharmacology and Therapeutics, 1988, 44, 335-342.	4.7	245
8	Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). Journal of Pain, 2015, 16, 1233-1242.	1.4	188
9	Attitudes Toward Opioid Use for Chronic Pain: A Canadian Physician Survey. Pain Research and Management, 2003, 8, 189-194.	1.8	128
10	Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis. Anesthesia and Analgesia, 2017, 125, 1638-1652.	2.2	115
11	A Clinical Evaluation of Transdermal Therapeutic System Fentanyl for the Treatment of Cancer Pain. Journal of Pain and Symptom Management, 1998, 16, 102-111.	1.2	96
12	Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. Journal of Pain, 2001, 2, 197-204.	1.4	89
13	An Open-Label, Multi-Dose Efficacy and Safety Study of Intramuscular Tetrodotoxin in Patients with Severe Cancer-Related Pain. Journal of Pain and Symptom Management, 2007, 34, 171-182.	1.2	81
14	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Using a Low-Frequency Magnetic Field in the Treatment of Musculoskeletal Chronic Pain. Pain Research and Management, 2007, 12, 249-258.	1.8	72
15	The analgesic efficacy of intrathecal d-ala2-d-leu5-enkephalin in cancer patients with chronic pain. Pain, 1985, 23, 213-221.	4.2	71
16	Treatment of Neuropathic Pain with Venlafaxine. Annals of Pharmacotherapy, 2001, 35, 557-559.	1.9	70
17	Management of Central Poststroke Pain. Stroke, 2015, 46, 2853-2860.	2.0	68
18	Fibromyalgia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 119, 513-527.	1.8	67

#	Article	IF	CITATIONS
19	Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement. Canadian Family Physician, 2017, 63, 844-852.	0.4	65
20	Buprenorphine Transdermal System for Opioid Therapy in Patients with Chronic Low Back Pain. Pain Research and Management, 2010, 15, 169-178.	1.8	61
21	PAIN IN CENTRAL AND PERIPHERAL DEMYELINATING DISORDERS. Neurologic Clinics, 1998, 16, 889-897.	1.8	60
22	Fibromyalgia: Presentation and Management with a Focus on Pharmacological Treatment. Pain Research and Management, 2008, 13, 477-483.	1.8	48
23	Unidirectional analgesic cross-tolerance between morphine and levorphanol in the rat. Pain, 1988, 33, 233-239.	4.2	47
24	Comparative Efficacy and Safety of Controlledâ€Release Morphine Suppositories and Tablets in Cancer Pain. Journal of Clinical Pharmacology, 1998, 38, 74-81.	2.0	43
25	Canadian Pain Society and Canadian Rheumatology Association Recommendations for Rational Care of Persons with Fibromyalgia. A Summary Report. Journal of Rheumatology, 2013, 40, 1388-1393.	2.0	43
26	Long-Term Outcome of the Management of Chronic Neuropathic Pain: A Prospective Observational Study. Journal of Pain, 2015, 16, 852-861.	1.4	41
27	The reciprocal associations between catastrophizing and pain outcomes in patients being treated for neuropathic pain: a cross-lagged panel analysis study. Pain, 2016, 157, 1946-1953.	4.2	38
28	Lower Functional Connectivity of the Periaqueductal Gray Is Related to Negative Affect and Clinical Manifestations of Fibromyalgia. Frontiers in Neuroanatomy, 2017, 11, 47.	1.7	38
29	Sensitivity of the DN4 in Screening for Neuropathic Pain Syndromes. Clinical Journal of Pain, 2018, 34, 30-36.	1.9	36
30	Systemic Drug Treatment for Chronic Musculoskeletal Pain. Clinical Journal of Pain, 2001, 17, S86-S93.	1.9	33
31	The doseâ€"Response relationship of controlled-release codeine (Codeine Contin) in chronic cancer pain. Journal of Pain and Symptom Management, 1994, 9, 363-371.	1.2	30
32	Pain-related Activity Management Patterns and Function in Patients With Fibromyalgia Syndrome. Clinical Journal of Pain, 2018, 34, 122-129.	1.9	30
33	Long-term safety, tolerability, and efficacy of OROS® hydromorphone in patients with chronic pain. Journal of Opioid Management, 2009, 5, 97-105.	0.5	27
34	A formal feasibility study of sublingual methadone for breakthrough cancer pain. Palliative Medicine, 2010, 24, 696-706.	3.1	26
35	Consensusâ€based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. International Journal of Clinical Practice, 2020, 75, e13871.	1.7	26
36	Structural and Functional Brain Changes at Early and Late Stages of Complex Regional Pain Syndrome. Journal of Pain, 2018, 19, 146-157.	1.4	22

#	Article	IF	CITATIONS
37	The Multidimensional Pain Inventory profiles in patients with chronic cancer-related pain: an examination of generalizability. Pain, 2000, 87, 75-82.	4.2	21
38	The Canadian STOP-PAIN Project. Clinical Journal of Pain, 2014, 30, 443-452.	1.9	21
39	Sex Differences in Psychological Response to Pain in Patients With Fibromyalgia Syndrome. Clinical Journal of Pain, 2015, 31, 425-432.	1.9	21
40	Factors Associated with Suicidal Ideation in Patients with Chronic Non-Cancer Pain. Pain Medicine, 2017, 18, pnw115.	1.9	21
41	A Phase II, multicenter, randomized, double-blind, placebo-controlled crossover study of CJC-1008—a long-acting, parenteral opioid analgesic—in the treatment of postherpetic neuralgia. Journal of Opioid Management, 2006, 2, 167-173.	0.5	21
42	Management of chronic neuropathic pain: a protocol for a multiple treatment comparison meta-analysis of randomised controlled trials. BMJ Open, 2014, 4, e006112.	1.9	18
43	Physical Functioning and Opioid use in Patients with Neuropathic Pain. Pain Medicine, 2015, 16, 1361-1368.	1.9	17
44	Basal Ganglia Perfusion in Fibromyalgia is Related to Pain Disability and Disease Impact. Clinical Journal of Pain, 2016, 32, 495-505.	1.9	17
45	Long-Term Outcomes in the Management of Central Neuropathic Pain Syndromes: A Prospective Observational Cohort Study. Canadian Journal of Neurological Sciences, 2018, 45, 545-552.	0.5	16
46	An Evaluation of Sex Differences in Patients With Chronic Pain Undergoing an Interdisciplinary Pain Treatment Program. Pain Practice, 2020, 20, 62-74.	1.9	14
47	Risk of Chronic Opioid Use After Radiation for Head and Neck Cancer: A Systematic Review and Meta-Analysis. Advances in Radiation Oncology, 2021, 6, 100583.	1.2	11
48	Long-Term Outcomes in the Management of Painful Diabetic Neuropathy. Canadian Journal of Neurological Sciences, 2017, 44, 337-342.	0.5	9
49	Fluctuating QTc interval in an asymptomatic patient treated with methadone for chronic pain. Journal of Opioid Management, 2005, 1, 73-76.	0.5	9
50	Use of Methadone for Neuropathic Pain. Pain Research and Management, 2003, 8, 131-132.	1.8	8
51	Design Process and Utilization of a Novel Clinical Decision Support System for Neuropathic Pain in Primary Care: Mixed Methods Observational Study. JMIR Medical Informatics, 2019, 7, e14141.	2.6	8
52	Evaluation of Dosing Guidelines for Use of Controlled-Release Codeine in Chronic Noncancer Plan. Pain Research and Management, 2003, 8, 143-148.	1.8	7
53	An Adaptive Role for Negative Expected Pain in Patients With Neuropathic Pain. Clinical Journal of Pain, 2015, 31, 438-443.	1.9	7
54	Spinal opioid analgesics and local anesthetics in the management of chronic cancer pain. Journal of Pain and Symptom Management, 1986, 1, 79-86.	1.2	6

#	Article	IF	Citations
55	Pain-Related Activity Management Patterns as Predictors of Treatment Outcomes in Patients with Fibromyalgia Syndrome. Pain Medicine, 2020, 21, e191-e200.	1.9	6
56	Segmental Hyperhidrosis as a Manifestation of Spinal and Paraspinal Disease. Canadian Journal of Neurological Sciences, 1998, 25, 325-327.	0.5	5
57	Modifications are suggested for the Special Interest Group (SIG) on Neuropathic Pain proposed definition and guidelines for neuropathic pain. Pain, 2011, 152, 1682.	4.2	5
58	Management of Pain in Patients With Cancer. Psychiatric Annals, 1984, 14, 815-822.	0.1	5
59	Opioid analgesics in the management of neuropathic pain. European Journal of Pain Supplements, 2007, 1, 57-60.	0.0	4
60	The Clinical Management of Neuropathic Pain. Pain Research and Management, 2006, 11, 30A-36A.	1.8	3
61	Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment. Canadian Journal of Pain, 2019, 3, 180-189.	1.7	3
62	Treatment outcome in a multidisciplinary cancer pain clinic by Banning et al Pain, 1991, 47, 127-128.	4.2	2
63	Does acute pain associated with herpes zoster respond to treatment with gabapentin?. Nature Clinical Practice Neurology, 2006, 2, 298-299.	2.5	2
64	Initial Pain Management Plans in Response to Severe Pain Indicators on Oncology Clinic Previsit Questionnaires. Pain Research and Management, 2014, 19, 309-312.	1.8	2
65	Opioid Analgesics in the Management of Neuropathic Pain. Pain Research and Management, 2000, 5, 89-91.	1.8	1
66	Managing Cancer Pain - Simple Rules, Major Benefits. Pain Research and Management, 2004, 9, 180-180.	1.8	0
67	Central Pain Syndrome: Pathophysiology, Diagnosis and Management. 2007. By Sergio Canavero, Vincenzo Bonicalzi. Published by Cambridge University Press. 382 pages. Price C\$95 Canadian Journal of Neurological Sciences, 2008, 35, 399-399.	0.5	0
68	The Opiate Receptors. Second Edition. 2011. Edited by Gavril W. Pasternak. Published by Humana Press. 516 pages. C\$230 approx Canadian Journal of Neurological Sciences, 2012, 39, 259-259.	0.5	0
69	Alternating Horner Syndrome With <i>Vegetative Alterna</i> and Spastic Quadraparesis After Bacterial Meningitis. JAMA Neurology, 2017, 74, 1504.	9.0	0
70	122: Risk of Chronic Opioid Use After Radiation for Head and Neck Cancer: A Systematic Review and Meta-Analysis. Radiotherapy and Oncology, 2020, 150, S53-S54.	0.6	0
71	Glial-modulating agents for the treatment of pain: protocol for a systematic review. BMJ Open, 2022, 12, e055713.	1.9	0